These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 38708591

  • 1. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M, Takayama A, Takeuchi M, Kawakami K.
    Diabetes Obes Metab; 2024 Aug; 26(8):3099-3109. PubMed ID: 38708591
    [Abstract] [Full Text] [Related]

  • 2. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH.
    Cardiovasc Diabetol; 2020 Nov 06; 19(1):188. PubMed ID: 33158436
    [Abstract] [Full Text] [Related]

  • 3. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Shen TH, Aby ES, Vock D, Farley JF.
    Diabetes Obes Metab; 2024 Nov 06; 26(11):5116-5125. PubMed ID: 39134463
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
    Kim J, Han K, Kim B, Baek KH, Song KH, Kim MK, Kwon HS.
    Diabetes Res Clin Pract; 2022 Dec 06; 194():110187. PubMed ID: 36442545
    [Abstract] [Full Text] [Related]

  • 5. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M.
    J Diabetes Investig; 2023 Mar 06; 14(3):404-416. PubMed ID: 36515129
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 06; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
    Takahashi H, Asakawa K, Kosakai Y, Lee T, Rokuda M.
    Diabetes Obes Metab; 2024 Mar 06; 26(3):997-1007. PubMed ID: 38086547
    [Abstract] [Full Text] [Related]

  • 8. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
    Kashiwagi A, Shoji S, Kosakai Y, Yoshinaga Y, Rokuda M.
    J Diabetes Investig; 2024 Mar 06; 15(3):374-387. PubMed ID: 38112598
    [Abstract] [Full Text] [Related]

  • 9. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
    Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y.
    J Diabetes Investig; 2022 Jul 06; 13(7):1175-1189. PubMed ID: 35243799
    [Abstract] [Full Text] [Related]

  • 10. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X, Zhang N, Lu L, Gao T, Chou OHI, Wong WT, Chang C, Wai AKC, Lip GYH, Zhang Q, Tse G, Liu T, Zhou J.
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb 23; 10(2):103-117. PubMed ID: 37962962
    [Abstract] [Full Text] [Related]

  • 11. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI, Chauhan VK, Chung CTS, Lu L, Lee TTL, Ng ZMW, Wang KKW, Lee S, Liu H, Pang RTK, Kaewdech A, Cheung BMY, Tse G, Zhou J.
    Gastric Cancer; 2024 Sep 30; 27(5):947-970. PubMed ID: 38856768
    [Abstract] [Full Text] [Related]

  • 13. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, Zhang Q, Chang C, Liu T, Tse G, Jing F, Cheung BMY.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1501-1510. PubMed ID: 36066415
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR, Ha KH, Lee K, Kim DJ.
    PLoS One; 2019 Apr 03; 14(10):e0224549. PubMed ID: 31658289
    [Abstract] [Full Text] [Related]

  • 18. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R, Patel A, Dahm L, Han C, Medders KE, Mowers R, Byington CL, Koliwad SK, Butte AJ.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2336613. PubMed ID: 37782497
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Effect of Sodium Glucose Cotransporter-2 Inhibitors on Hemoglobin A1c Variability and Acute Kidney Injury: A Causal Mediation Analysis.
    Wang T, Ji D, Stürmer T, Ismail S, Dong S, Shen P, Lin H, Shi L, Guan X, Xu Y.
    Pharmacoepidemiol Drug Saf; 2024 Aug 02; 33(8):e5876. PubMed ID: 39090775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.